Table 2.

Adverse events

Adverse events	Total (n = 71)	Child–Pugh class A or B (n = 54)	Child–Pugh class C (n = 17)	p value
Any adverse events	14 (19.7%)	8 (14.8%)	6 (35.3%)	0.08
Death	2 (2.8%)	1 (1.9%)	1 (5.9%)	0.42
Serious adverse events (CTCAE grade ≥ 4)	4 (5.6%)	2 (3.8%)	2 (11.8%)	0.24
Adverse events leading to treatment discontinuation	2 (2.8%)	2 (3.8%)	0 (0.0%)	1.00
CTCAE grade
Grade 1	5 (7.0%)	3 (5.7%)	2 (11.8%)	0.59
Grade 2	2 (2.8%)	1 (1.9%)	1 (5.9%)	0.42
Grade 3	3 (4.2%)	2 (3.8%)	1 (5.9%)	0.57
Grade 4	2 (2.8%)	1 (1.9%)	1 (5.9%)	0.42
Grade 5	2 (2.8%)	1 (1.9%)	1 (5.9%)	0.42
Adverse events
Nosebleed	1 (1.4%)	0 (0.0%)	1 (5.9%)	0.24
Dysgeusia	1 (1.4%)	1 (1.9%)	0 (0.0%)	1.00
Hepatic encephalopathy	2 (2.8%)	2 (3.8%)	0 (0.0%)	1.00
Progression of diabetes mellitus	1 (1.4%)	0 (0.0%)	1 (5.9%)	0.24
Esophageal varices rupture	2 (2.8%)	1 (1.9%)	1 (5.9%)	0.42
Acute cholecystitis	1 (1.4%)	1 (1.9%)	0 (0.0%)	1.00
Deterioration of ascites	2 (2.8%)	1 (1.9%)	1 (5.9%)	0.42
Fatigue	1 (1.4%)	0 (0.0%)	1 (5.9%)	0.24
Pharynx discharge	1 (1.4%)	1 (1.9%)	0 (0.0%)	1.00
Liver failure	1 (1.4%)	0 (0.0%)	1 (5.9%)	0.24
Laboratory abnormalities
Total bilirubin elevation	1 (1.4%)	1 (1.9%)	0 (0.0%)	1.00

Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0, as presented by the National Cancer Institute Cancer Therapy Evaluation Program